A Double- Blind, Randomized, Placebo and Active Controlled, Multi-Center Study to Investigate Efficacy and Safety After Oral Administration of 2 and 3 mg ZK 283197, 1 mg 17ß-Estradiol and Placebo Once Daily for 8 Weeks in Postmenopausal Women With Hot Flushes.
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2015
At a glance
- Drugs ZK 283197 (Primary) ; Estradiol
- Indications Hot flashes
- Focus Therapeutic Use
- Sponsors Bayer
- 01 Sep 2012 Planned number of patients changed from 112 to 118.
- 05 Feb 2009 Actual patient numbers (112) added as reported by ClinicalTrials.gov.
- 05 Feb 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.